p53 and ERK1/2 usually play an opposite role in cancer cell survival, as p53 activation may induce cell cycle arrest or apoptosis [14] while ERK1/2, a pathway activated downstream of growth factor receptors or RAF/RAF protein kinases, essentially sustains cancer cell growth [15]. This evidence concerns the gene TP53 and cancer.